Global high-intensity focused ultrasound (HIFU) market is estimated to be valued at US$ 112.7 million in 2023 and is expected to exhibit a CAGR of 7.16% during the forecast period (2023-2030). Increase in company partnerships and collaboration between market players is expected to drive the market words over forecast period. Moreover increase in number of product approvals by regulatory authorities is expected to drive the market growth.
Analysts’ Views on Global High- Intensity Focused Ultrasound (HIFU) Market:
Increasing cases of neurological disorders can boost the market growth over forecast period due to increasing usage of HIFU in the treatment of neurological disorders. For instance, according to The Lancet, in July 2021, the prevalence of non-communicable neurological disorders was doubled in 2019 globally, as compared to 1990. Non-communicable neurological disorders represented 4.0% of all disease globally in 1990 and by 2019 that percentage had doubled to 8.2%
Figure 1. Global High Intensity Focused Ultrasound (HIFU) Market Share (%), By Imaging Technology, 2023
Global High Intensity Focused Ultrasound (HIFU) Market- Driver
Company Partnerships
Major companies operating in the global high-intensity focused ultrasound (HIFU) market are focused on inorganic growth strategies such as partnerships, which is expected to drive growth of the global High-Intensity focused ultrasound (HIFU) market over the forecast period. For instance, in December 2020, Koninklijke Philips N.V., a multinational conglomerate corporation, partnered with Insightec, a medical device company to expand access to MR (Magnetic Resonance)-guided focused ultrasound for incision-less neurosurgery. By developing compatibility between Koninklijke Philips N.V’s advanced MR systems and InSightec's Exablate Neuro platform, these two companies will enable greater access to MR-guided focused ultrasound for the treatment of Essential Tremor and other neurological disorders. Insightec's Exablate Neuro platform is a magnetic resonance image-guided focused ultrasound (MRgFUS) system that treats tremors which are not treatable with medications.
Increasing Prevalence of Prostate Cancer
Increasing prevalence of prostate cancer is expected to drive the market growth over the forecast period as HIFU is used to treat prostate cancer. For instance, according to American Society of Clinical Oncology, in February 2022, worldwide, 1,414,259 people were diagnosed with prostate cancer in the year 2020.
Figure 2. Global High-Intensity Focused Ultrasound (HIFU) Market Share (%), By Region, 2023
Global High- Intensity Focused Ultrasound (HIFU) Market- Regional Analysis
Among regions, North America is expected to dominate the market over the forecast period, due to the increasing prevalence of vaginal and vulvar cancer in that region. For instance, according to the Centers for Disease Control and Prevention, in November 2022, in U.S., 1,368 women were diagnosed with vaginal cancer and 5,579 women were diagnosed with vulvar cancer in 2019.
Europe is expected to hold second position in global high-intensity focused ultrasound (HIFU) market over the forecast period due to increasing collaborations by key players in that region. For instance, in June 2021, Theraclion, a France- based company developing a scalable robotic platform for non-invasive ultrasound therapy, announced a phase-2 collaboration with the University of Virginia Cancer Center. This will expand research activity in the use of Theraclion’s HIFU system in the treatment of early-stage breast cancer.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 112.7 Mn |
| Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 to 2030 |
| Forecast Period 2023 to 2030 CAGR: | 7.16% | 2030 Value Projection: | US$ 182.9 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Koninklijke Philips N.V., Sonic Concepts, Inc., Theraclion, Sonablate, Alpinion Medical Systems Co., Ltd., Shanghai Carnation Medical Technology Co., Ltd., Insightec, FUS Instruments Inc., Mianyang Sonic Electronic, Profound Medical, Merz Pharmaceuticals GmbH, Image Guided Therapy, and Promedica Bioelectronics s.r.l. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global High-Intensity Focused Ultrasound (HIFU) Market- Impact of Coronavirus (COVID-19) Pandemic
According to World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till January 16, 2023, worldwide 663,640,386 people were affected.
The COVID-19 pandemic had a negative impact on the global high- intensity focused ultrasound (HIFU) market due to reduced participation in screening programs and diagnosis to surgery/radiotherapy for the cancer treatment. For instance, according to an article published in Future Science, an open access journal, in January 2022, a retrospective study was performed at the University Hospitals of Verona to analyze radiotherapy usage in April, May, and June 2019, in comparison with June 2020. It was found that there was decrease in weekly radiotherapy usage. It was decreased by 19.9% in April, 6.2% in May and 11.6% in June 2020 respectively compared with corresponding months in 2019.
Global High-Intensity Focused Ultrasound (HIFU) Market Segmentation:
The global High-Intensity focused ultrasound (HIFU) market report is segmented into imaging technology, indication and end user
Based on Imaging Technology, the market is segmented into, ultrasound- HIFU therapy and magnetic resonance imaging- HIFU therapy. Out of which, magnetic resonance imaging- HIFU therapy segment is expected to dominate the global high-intensity focused ultrasound (HIFU) market during the forecast period and this is attributed due to increasing R&D activities regarding magnetic resonance imaging- HIFU therapy
Based on Indication, the market is segmented into oncology (Prostate cancer, Rectal tumors, Liver tumors, Renal tumors, others), skin care (Anti-aging treatment, Skin Laxity and Tightening, Others), neurological disorders, and others (Uterine Fibroids, Benign Prostatic Hyperplasia, etc.). Out of which, oncology segment is expected to dominate the market over the forecast period and this is attributed due to increasing usage of High-Intensity focused ultrasound (HIFU) for the treatment of various cancer/tumor types.
Based on End User, global High-Intensity focused ultrasound (HIFU) market is segmented into hospitals, ambulatory surgical centers, dermatology clinics, and others (Research Institutes, Specialty Centers, etc). Hospitals segment is expected to dominate the market over the forecast period and this is attributed to the usage of HIFU in oncology department in hospitals.
Based on Region, global High-Intensity focused ultrasound (HIFU) market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. North America is expected to dominate the market over the forecast period and this is attributed to the increase in number of product approvals from regulatory authorities.
Among all segmentation, ultrasound- HIFU therapy segment has highest potential due to increasing research and development activities about ultrasound- HIFU therapy. For instance, in September 2020, The Hospital of Vestfold, a Hospital in Norway, initiated a study for high-intensity focused ultrasound HIFU therapy, for the treatment local tumor control in patients having prostate cancer. The study is expected to complete by September 2030.
Global High-Intensity Focused Ultrasound (HIFU) Market Cross Sectional Analysis:
Among imaging technology, Ultrasound- HIFU Therapy held as a dominant segment in 2023 in North America region due to increasing product launches. For instance, in November 2022, TOOsonix A/S, a company in High-Intensity focused ultrasound (HIFU) technology for dermatology, announced that United States Patent and Trademark Office (USPTO) has granted a U.S. patent no. 11/491,351 for its non-invasive treatments of dermatological conditions.
In indication segment, oncology segment is dominant in North America region due to increasing R&D activities. For instance, in November 2022, National Cancer Institute (NCI), a U.S. Government agency for cancer research, initiated a study on Prostate Cancer using radiation therapy. The study is in phase- 2 of clinical trials and is expected to complete by December 2028.
Global High-Intensity Focused Ultrasound (HIFU) Market: Key Developments
In November 2022, Nomura Holdings, Inc., a Japan- based financial holding company, acquired shares of SONIRE Therapeutics Inc., a company developing a next-generation high-intensity focused ultrasound (HIFU) treatment system. The investment made by the Nomura Holdings, Inc. will benefit the SONIRE Therapeutics Inc. to develop a HIFU treatment system for the treatment of pancreatic cancer as well as other types of cancers.
In November 2021, Zealand University Hospital started a research on HIFU for the treatment of Basal Cell Carcinoma (BCC). The investigation entails assessing the safety and efficacy profile of three months after a single 3-5 minute treatment. Secondary endpoints are followed up on every third month, until the study concludes one year after treatment. The study is expected to complete by December 2024.
In November 2020, EDAP TMS, a medical device company that develops, manufactures, and markets minimally invasive medical devices using ultrasound technology for various medical applications, announced a distribution agreement with AB Medica, an Italy-based company specialized in creation and distribution of medical technologies. The agreement between two companies will extend the availability of EDAP TMS’s High-Intensity Focused Ultrasound (HIFU) technology across Italy.
Hospices Civils de Lyon, France's second university hospital center (CHU) initiated a study evaluating the efficacy and tolerability of focused HIFU (High Intensity Focused Ultrasound) therapy compared to active surveillance in patients with significant low risk prostate cancer. The study is in phase 3 of clinical trials and is expected to be complete in October 2026.
Global High-Intensity Focused Ultrasound (HIFU) Market: Restraint
High cost of High-Intensity focused ultrasound (HIFU)
The major factor that can hamper growth of the global High-Intensity focused ultrasound (HIFU) market over the forecast period includes the high cost of HIFU treatment. For instance, average price of High-Intensity focused ultrasound ablation (HIFU) is US$ 10,700.
However, increasing introduction of reimbursement for High-Intensity focused ultrasound (HIFU) by governments of various countries may help in tackling the issue of high cost of HIFU treatment
Global High-Intensity Focused Ultrasound (HIFU) Market: Key Players
Major players operating in the global High-Intensity focused ultrasound (HIFU) market include Koninklijke Philips N.V., Sonic Concepts, Inc., Theraclion, Sonablate, Alpinion Medical Systems Co., Ltd., Shanghai Carnation Medical Technology Co., Ltd., Insightec, FUS Instruments Inc., Mianyang Sonic Electronic, Profound Medical, Merz Pharmaceuticals GmbH, Image Guided Therapy, and Promedica Bioelectronics s.r.l.
Definition: High-Intensity focused ultrasound (HIFU) is a medical procedure that uses ultrasound waves to treat conditions such as tumor. It is a non-invasive procedure and uses focused ultrasound waves to thermally ablate a portion of tissue, by destroying it with intense heat. The intense heat causes tissue coagulation, necrosis, cavitation, and heat shock in the cells, resulting in the destruction of the ablated tissue.
High intensity focused ultrasound (HIFU) is a novel, non-invasive treatment that is used to treat a wide range of tumors and diseases. HIFU uses an ultrasound transducer that has higher energy as compared to those used for diagnostic imaging. The transducer focuses on sound waves to generate heat at a single point within the body and destroys the target tissue. MRI images are used to plan the treatment and monitor the degree of heating in real time. Deep tissue penetration and thermal and mechanical interactions with human tissue are possible with ultrasound. With the development of high intensity focused ultrasound, a number of solid malignant tumors, such as those of the pancreas, liver, kidney, bone, prostate, and breast, as well as uterine fibroids and soft-tissue sarcomas, are clinically treatable. High intensity focused ultrasound and magnetic resonance imaging can be combined to provide real-time imaging during ablation. HIFU has advantages such as:
HIFU is also used in the treatment of facial aging. According to the American Board of Cosmetic Surgery, nonsurgical ultrasound treatments such as HIFU can:
Market Dynamics
Increasing prevalence of rectal cancer is expected to drive the market growth over the forecast period. For instance, according to American Society of Clinical Oncology (ASCO), in May 2022, 732,210 people were diagnosed with rectal cancer in the year 2020.
Increasing number of research and development activities by research institutes is expected to drive the market growth over forecast period. For instance, Institute Mutualiste Montsouris, a General hospital in France, initiated a study to investigate the efficacy and safety of terbinumab combined with chemotherapy in neoadjuvant therapy of triple-negative breast cancer after HIFU therapy. The study is in phase 2 of clinical trials and is expected to complete by December 2024.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients